NUREXONE BIOLOGIC INC. (J90) — Financial Flexibility Index
NUREXONE BIOLOGIC INC. (J90) has a Financial Flexibility Index of -0.88x as of December 2025. Free cash flow of €-1.17 Million (operating CF €-1.17 Million minus capex €9.00K) represents -1% of total liabilities (€1.32 Million).
Financial Flexibility Index
Free Cash Flow
Total Liabilities
Capital Expenditures
NUREXONE BIOLOGIC INC. Financial Flexibility Index (2021–2025)
Historical Financial Flexibility Index trend for NUREXONE BIOLOGIC INC. across 5 annual periods. See NUREXONE BIOLOGIC INC. (J90) working capital ratio to evaluate short-term liquidity relative to the company's equity base.
Annual Financial Flexibility Index for NUREXONE BIOLOGIC INC. (2021–2025)
Year-by-year free cash flow to debt coverage for NUREXONE BIOLOGIC INC.. For the full company profile including market capitalisation, see NUREXONE BIOLOGIC INC. (J90) market capitalisation.
| Year | Flexibility Index | Free Cash Flow (EUR) | Operating CF | Total Liabilities | YoY Change |
|---|---|---|---|---|---|
| 2025 | -3.36x | €-4.46 Million | €-4.51 Million | €1.32 Million | ▲ +46.1% |
| 2024 | -6.23x | €-4.24 Million | €-4.89 Million | €680.00K | ▼ -337.8% |
| 2023 | -1.42x | €-2.82 Million | €-2.94 Million | €1.98 Million | ▲ +73.8% |
| 2022 | -5.44x | €-3.80 Million | €-3.85 Million | €698.00K | ▼ -632.3% |
| 2021 | -0.74x | €-1.23 Million | €-1.23 Million | €1.66 Million | — |